Vaccination clinic begins Tuesday at MD...
Following receipt of the Pfizer COVID-19 vaccine on Monday morning, MD Anderson’s Pharmacy, Infection Control, Employee Health and clinical and facilities experts re-reviewed protocols and procedures, and an initial vaccination clinic simulation was completed. Based on those successful efforts along with a manager briefing and employee town hall, positive feedback from managers about employee engagement and swift uptake of...
MD Anderson researcher elected to ASCO Board of Directors
Mariana Chavez Mac Gregor, M.D., M.Sc., associate professor in Health Services Research with a joint appointment in Breast Medical...
COVID-19 vaccine delivery and distribution statement from MD...
The University of Texas MD Anderson Cancer Center is prepared to accept, store and distribute the Pfizer COVID-19 vaccine following...
Combination of chemotherapy and blinatumomab improves survival for...
ABSTRACT 464
A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of...
CAR T cell therapy effective as first-line treatment for...
ABSTRACT 405
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous...
Novel antibody-drug conjugate shows promising early results...
ABSTRACT 167
A phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center found IMGN632, a novel...
Five MD Anderson researchers elected AAAS Fellows
In recognition of their achievements in advancing cancer research, five faculty members from The University of Texas MD...
New targeted therapy blocks metabolism in brain cancer...
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel targeted therapy, called POMHEX, which blocks...
MD Anderson joins thousands of top U.S. hospitals encouraging...
The University of Texas MD Anderson Cancer Center and more than 100 of the nation’s top health care systems, representing thousands of...
A Conversation With a Living Legend honoring Admiral William H....
The North Texas A Conversation With a Living Legend® raised $1 million this week in a virtual version of the signature fundraising...
MD Anderson and Obsidian Therapeutics announce strategic...
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced a multi-year strategic collaboration...
Sherry Adkins receives Brown Foundation Award for Excellence in...
Sherry Adkins is the recipient of the 2020 Brown Foundation Award for Excellence in Oncology Nursing at The University of Texas MD...
MD Anderson announces fifth annual class of Andrew Sabin Family...
The University of Texas MD Anderson Cancer Center has named 10 early-career faculty members to the 2020 class of Andrew Sabin Family...
MD Anderson researchers present immunotherapy advances at...
ABSTRACTS 277, 368, 420
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight...
Large-scale cancer proteomics study profiles protein...
Through large-scale profiling of protein changes in response to drug treatments in cancer cell lines, researchers at The University of...
MD Anderson and UT Austin collaboration to end cancer welcomed...
A new collaboration combining cancer research with advanced computing and computational modeling techniques received strong engagement...
Stereotactic radiosurgery recommended for patients with...
Researchers from The University of Texas MD Anderson Cancer Center have conducted the first randomized clinical trial comparing...
MD Anderson's fifth annual Boot Walk to End Cancer® goes...
HOUSTON ― The University of Texas MD Anderson Cancer Center will host the fifth annual Boot Walk to End Cancer® virtually on Saturday,...
Focus Fund and MD Anderson launch investment fund to...
The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched Cancer Focus Fund, LP, an...
MD Anderson, UT Austin Announce First Collaborative Projects in...
Cancer remains one of the leading causes of death worldwide. While advances in cancer diagnoses and treatments are promising, more is...
MD Anderson and Allogene Therapeutics announce strategic...
The University of Texas MD Anderson Cancer Center and Allogene Therapeutics, Inc. today announced a strategic five-year collaboration...
MD Anderson earns fifth Magnet designation for nursing...
The University of Texas MD Anderson Cancer Center today announced achievement of its fifth consecutive Magnet designation, the highest...
Dual checkpoint blockade promising as pre-surgical approach...
Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab...
Study identifies characteristics of infused CAR T cells...
Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19...
Study finds cancer mutations accumulate in distinct regions...
A new study from researchers at The University of Texas MD Anderson Cancer Center has discovered that mutations found in cancers do...
Next-gen bioinformatics tool enables big data analysis...
A new data analysis tool developed by researchers at The University of Texas MD Anderson Cancer Center incorporates a user-friendly,...
MD Anderson and Taiho Pharmaceutical announce collaboration...
The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic...
Monica Johnson receives Julie and Ben Rogers Award for Excellence
The University of Texas MD Anderson Cancer Center has awarded Monica Johnson, M.H.A., C.P.X.P., the Julie and Ben Rogers Award for...
KRAS inhibitor sotorasib appears safe, achieves durable...
ABSTRACT: 1257O
In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C...
New study from MD Anderson and BridgeBio’s Navire Pharma...
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma,...
Combination immunotherapy benefits subset of patients with...
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of...
MD Anderson and Astex Pharmaceuticals announce strategic...
The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical...
MD Anderson and Xencor enter strategic collaboration to...
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic collaboration to study...
MD Anderson welcomes 15 volunteer board members, honors two...
The University of Texas MD Anderson Cancer Center Board of Visitors (BOV) has named 15 new members and bestowed its highest honor of...
Lung cancer trial of RET inhibitor selpercatinib achieves...
For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well...
$24 million in CPRIT funding awarded to MD Anderson and related...
The University of Texas MD Anderson Cancer Center today was awarded nearly $9 million from the Cancer Prevention and Research...
Targeted therapy combination effective for patients with...
In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF...
Study shows frequently used serology test may not detect...
Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to...
Combination therapy significantly improves survival...
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain...
Cancer care and screenings must remain a priority during...
The University of Texas MD Anderson Cancer Center is committed to safely providing patient care and cancer screenings throughout the...
Implementation of social distancing policies correlates...
According to researchers from The University of Texas MD Anderson Cancer Center, the implementation of social distancing policies...
MD Anderson honored to rank as nation’s best hospital for...
The University of Texas MD Anderson Cancer Center is honored to rank No. 1 in cancer care in the U.S. News & World Report’s 2020...
MD Anderson and Sanofi announce strategic collaboration to...
The University of Texas MD Anderson Cancer Center and Sanofi today announced a five-year strategic collaboration to accelerate the...
MD Anderson and UT Austin Create Unique Data-Driven Collaboration...
The University of Texas MD Anderson Cancer Center and two institutions at The University of Texas at Austin – the Oden Institute for...
Public Notice of Scheduled Site Visit to MD Anderson by ANCC...
Public Notice
MAGNET RECOGNITION PROGRAM® — SITE VISIT
· The University of Texas...
Study shows sedentary behavior independently predicts...
In the first study to look at objective measures of sedentary behavior and cancer mortality, researchers from The University of Texas...
Combination biomarker predicts response to immune...
In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved...
MD Anderson and Philips collaborate to facilitate personalized...
The University of Texas MD Anderson Cancer Center and Royal Philips today announced a collaboration to provide oncologists with...
MD Anderson and Rakuten Medical announce strategic alliance to...
The University of Texas MD Anderson Cancer Center and Rakuten Medical, Inc. today announced a strategic alliance collaboration...
Statement from Peter WT Pisters, M.D., regarding the tragic death...
At MD Anderson, we are filled with anguish and deep sorrow over the senseless acts of racism and violence in our country and the...
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows...
ABSTRACT: #102
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the...
Targeted therapy pralsetinib achieves high response rates...
ABSTRACT: #109
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad...
Targeted therapy tepotinib for non-small cell lung cancer...
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective...
Novel targeted drug induced positive response for patients...
ABSTRACT: #5003
In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with...
Combination therapy well-tolerated and highly effective for...
ABSTRACT: #7500
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be...
MD Anderson and Innovent Biologics announce a strategic...
The University of Texas MD Anderson Cancer Center and Innovent Biologics, Inc. today announced a strategic collaboration agreement to...
Patients with advanced BRCA-mutated breast cancer found no...
ABSTRACT: CTO71
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center...
MD Anderson, Ipsen advance new therapy with potential...
ABSTRACT: DDT01-03
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1),...
MD Anderson genetics expert Guillermina Lozano elected to...
Guillermina Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected as...
MD Anderson implements proactive measures due to 2019 novel...
The University of Texas MD Anderson Cancer Center is committed to keeping our patients, our workforce members and our community safe...
Majority of patients responded in CAR T-cell trial for...
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell...
Immunotherapy effective in metastatic prostate cancers with...
Although metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of patients...
New therapeutic strategies proposed for some lung and...
New findings from researchers at The University of Texas MD Anderson Cancer Center about how some cancer cells become “addicted” to...
Combination creates powerful central memory T cells for...
Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab...
Study sheds light on fatty acid’s role in “chemobrain” and...
Medical experts have always known myelin, the protective coating of nerve cells, to be metabolically inert. A study led by The...
Pembrolizumab shows promise for some advanced,...
A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-tumor...
MD Anderson returning to normal operations on Monday, March 2
The University of Texas MD Anderson Cancer Center is preparing to return to normal operations on Monday morning, March 2, after...
Combined therapy may improve clinical responses for...
A study at The University of Texas MD Anderson Cancer Center discovered a novel therapeutic vulnerability for patients who have tumors...
Osteosarcoma profiling reveals why immunotherapy remains...
Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the...
MD Anderson announces strategic collaboration with Denali...
The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration with Denali Therapeutics Inc. to...
MD Anderson receives more than $20 million in CPRIT funding
The University of Texas MD Anderson Cancer Center today was awarded more than $20 million from the Cancer Prevention and Research...
Houston Dash join Dynamo, MD Anderson in Making Cancer...
The University of Texas MD Anderson Cancer Center today announced the Houston Dash will join the institution's efforts toward one...
Absent p53, oral cancers recruit and reprogram nerves to...
Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function...
CD19 CAR NK-cell therapy achieves 73% response rate in...
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived...
Study provides new understanding of mitochondria genome...
A study led by The University of Texas MD Anderson Cancer Center furthered understanding about mitochondria, the cell components known...
MD Anderson supports World Cancer Day through dedication to...
The University of Texas MD Anderson Cancer Center honors World Cancer Day, Feb. 4, as the campaign celebrates 20 years of bringing...
Study demonstrates liquid biopsy as effective predictor of...
A study at The University of Texas MD Anderson Cancer Center showed that circulating tumor cells (CTCs), a form of liquid biopsy, was...
Lung cancer screening decision aid delivered through...
In the first comparative clinical trial of lung cancer screening decision aid versus standard educational information, researchers...
MD Anderson’s deemed status restored; re-accreditation completed
The University of Texas MD Anderson Cancer Center has announced that the Texas Health and Human Services Commission, on behalf of the...
Craig Owen Named Chief Information Officer
The University of Texas MD Anderson Cancer Center today named Craig Owen as its chief information officer. Owen has served the...
B-cell enrichment predictive of immunotherapy response in...
The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within specialized...
Study shows protein inhibitor as potential treatment...
A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common...